what is cryptocurrency investing- Top Featured

Since the beginning of this year, favorable policies for mergers and acquisitions have been frequent. Since the CSRC issued the Opinions on Deepening the Market Reform of Listed Companies' M&A and Restructuring on September 24th, the support of all parties to the M&A and restructuring market has continued to increase, and the M&A and restructuring market has continued to be active.From the perspective of institutional attention, Zhongwei Company and Weir Co., Ltd. have more than 30 institutional ratings, while Hengxuan Technology, Lanqi Technology, UIH Medical and Microelectrophysiology -U have more than 20 institutional ratings.[The time is ripe for Shanghai stocks to become monsters in batches! 】

After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).

It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.In addition, the market value of Zhongwei Company, Weir Shares and UIH Medical all exceeded 100 billion yuan.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.